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1. Introduction 
The cloning of leptin in 1994 introduced a novel concept about white adipose tissue (WAT) 
(Zhang et al., 1994). Actually, WAT has been recognized as an active tissue able to produce a 
wide variety of factors, called adipokines. These molecules participate through endocrine, 
paracrine, autocrine or juxtacrine cross-talk in a great variety of physiological or 
physiopathological processes, including food intake, insulin sensitivity, immunity and 
inflammation (Trayhurn & Wood, 2004, 2005). 
Moreover, adipokines represent a new family of compounds that can be currently 
considered as key players of the complex network of soluble mediators involved in the 
pathophysiology of rheumatic diseases. Adipokines include classic pro-inflammatory 
proteins such as TNF-ǂ and IL-6, both secreted by adipocytes, but synthesized also by 
immune cells infiltrating WAT, such as macrophages (Flower et al., 2003; Hotamisligil et al, 
1993; Trayhurn et al., 2006). 
These pro-inflammatory adipokines appear to significantly contribute to the so-called “low 
grade inflammation” of obese subjects, a condition associated with increased risk of cancer, 
type 2 diabetes, cardiovascular complications, autoimmune and inflammatory diseases 
including rheumatic diseases such as rheumatoid arthritis (RA), osteoarthritis (OA) and 
systemic lupus (SLE) (Ahima et al, 1996). For instance, it has been reported that obesity that 
is characterized by abnormal fat accumulation and dysfunction increases the incidence of 
osteoarthritis (OA). A prevailing hypothesis is that obesity increases mechanical loading on 
the articular cartilage that finally leads to its degeneration. However, obesity is also 
associated with OA in non-weight bearing joints such as hand joints, which suggest that 
metabolic factors, as adipokines, contribute to the high prevalence of OA in obese subjects 
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(Felson, 2005; Oliveria et al., 1999). Furthermore, adipokines play a pivotal role in other 
autoimmune and rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE). 
In this book chapter we review the role of adipokines in inflammation and immune 
response in the context of rheumatic diseases. 
2. Leptin 
Leptin is the protein product of the ob gene, the murine homologue of the human gene LEP, 
cloned in 1994 (Zhang et al, 1994). This adipokine is mainly produced by white adipose cells 
and its plasma concentration is directly correlated with the body-fat stores. It has a central 
role in fat metabolism; in fact leptin is considered a major regulator of body weight by 
suppressing appetite and stimulating energy expenditure via hypothalamic receptors. This 
hormone decreases food intake by inducing anorexigenic factors as cocaine amphetamine 
related transcript (CART) and increases energy consumption by suppressing orexigenic 
neuropeptides such as neuropeptide Y (NPY). The biological activity of leptin is mediated 
by specific receptors (Ob-R) that belong to the class 1 cytokine receptor superfamily, and are 
encoded by the gene diabetes (db). Alternative splicing of the db gene produce multiple 
isoforms, but only the long isoform Ob-Rb, appears to be capable of transducing the leptin 
signal.  
Leptin is a hormone with pleiotropic actions. In fact, in addition to regulation of food intake, 
it also affects a variety of other physiological functions, including fertility, bone metabolism, 
inflammation, infection, immune responses and others. Recent evidence demonstrates an 
involvement of leptin in promoting the pathogenesis of different autoimmune and 
rheumatic diseases such as rheumatoid arthritis, multiple sclerosis and SLE. Several authors 
have demonstrated a dependence between the risk of aggressive course of RA and leptin 
levels (Kadowaki & Yamauchi, 2005; Lee et al., 2007; Targonska-Stepniak et al., 2008; 
Whitehead et al., 2006). It is widely accepted that leptin levels are elevated in patients with 
RA and that there is a correlation between serum leptin and synovial fluid/serum leptin 
ratio and disease duration and parameters of RA activity (Olama et al., 2010). Generally, 
leptin is considered to be pro-inflammatory, but this hormone has been also reported to 
reduce radiographic joint damage (Rho et al., 2009). This effect could be related to some 
leptin anabolic effects, such as the stimulation of the synthesis of insulin-like growth factor-1 
(IGF-1) and transforming growth factor-ǃ (TGF- ǃ) at both the messenger RNA (mRNA) and 
protein levels (Dumond et al., 2003) 
The actions of leptin in RA are not only targeted to articular tissues, this adipokine also 
exerts direct modulatory effects on activation, proliferation, maturation and production of 
inflammatory mediators in a variety of immune cells, including lymphocytes, NK cells, 
monocytes/macrophages, dendritic cells, neutrophils and eosinophils (Lam & Lu, 2007). In 
particular, it is known that leptin is able to modulate T regulatory cells that are potent 
suppressors of autoimmunity. The group of Matarese et al, has recently demonstrated that 
leptin secreted by adipocytes sustains Th1 immunity by promoting effector T cell 
proliferation and by constraining Treg cells expansion. Weight loss, with concomitant 
reduction in leptin levels, induces a reduction in effector T cell proliferation and an 
increased expansion of Treg cells leading to a down-regulation of Th1 immunity and cell-
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mediated autoimmune diseases associated with increased susceptibility to infections. On the 
other hand, an increase in adipocyte mass leads to high leptin secretion, which results in 
expansion of effector T cells and reduction of T-Reg cells. This effect determines an overall 
enhancement of the pro-inflammatory immunity and of T cell-mediated autoimmune 
disorders. These data suggests that leptin can be considered as a link between immune 
tolerance, metabolic function and autoimmunity and that future strategies aimed at 
interfering with leptin signaling may represent innovative therapeutic tools for autoimmune 
disorders. 
Very recently it has been demonstrated that leptin can activate the mammalian target of 
rapamycin (mTOR) and regulate the proliferative capacity of regulatory T (TReg) cells. The 
study of Procaccini et al describes the leptin–mTOR signalling pathway as an important link 
between host energy status and TReg cell activity. The authors conclude that oscillating 
mTOR activity is necessary for TReg cell activation and suggest that this may explain why 
TReg cells are unresponsive to TCR stimulation in vitro, where high levels of leptin and 
nutrients may sustain mTOR activation (De Rosa et al., 2007; Procaccini et al., 2010).  
Leptin also may acts as a catabolic factor involved in the pathogenesis of osteoarthritis. 
In fact, Otero et al have demonstrated that in cultured human and murine chondrocytes 
type 2 nitric oxide synthase (NOS2) is synergistically activated by the combination of leptin 
plus interferon-Ǆ, and NOS2 activation by IL-1ǃ is increased by leptin via a mechanism 
involving JAK2, PI3K, and mitogen activated kinases (MEK1 and p38) (Otero M et al., 2003, 
2005). Nitric oxide (NO), which is induced by a wide range of pro-inflammatory cytokines, 
is a well-known pro-inflammatory mediator on joint cartilage, where it triggers chondrocyte 
phenotype loss, apoptosis, and metalloproteinases (MMPs) activation. 
Recently, it was demonstrated that leptin is able to induce also the expression of MMPs 
involved in OA cartilage damage, such as MMP-9 and MMP-13 (Toussirot et al., 2007). 
Leptin alone and in combination with IL-1ǃ up-regulates MMP-1 and MMP-3 production in 
human OA cartilage through the transcription factor NF-κB, protein kinase C and MAP 
kinase pathways. This hormone is also correlated positively to MMP-1 and MMP-3 in 
synovial fluid (SF) from OA patients (Koskinen et al., 2011).  
It is noteworthy that leptin was recently shown to increase IL-8 production in human 
chondrocytes (Lago et al., 2008). 
Bao et al have defined that leptin enhanced both gene and protein levels of catabolic factors 
such as MMP-2 y MMP-9, while down-regulated the anabolic factors such as bFGF in 
articular cartilage of rats. Additionally, the gene expression of ADAMTS-4 and -5 were 
markedly increased and was observed a depletion of proteoglycan in articular cartilage after 
treatment with leptin (Bao et al., 2010) 
Leptin also could contribute to abnormal osteoblast function in OA. In fact, the elevated 
production of leptin in OA abnormal subchondral osteoblast is correlated with the increased 
levels of ALP (alkaline phosphatase), OC, collagen type I and TGF-ǃ1 inducing a 
dysregulation of osteoblast function (Mutabaruka et al., 2010). 
Leptin’s and leptin receptor (Ob-Rb) expression levels were significantly increased in 
advanced OA cartilage and in SF. The induction by leptin of IL-1ǃ production y MMP-9 and 
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MMP-13 protein expression in chondrocytes indicates a pro-inflammatory and catabolic role 
of this hormone on cartilage metabolism (Simopoulou et al., 2007). 
Ku et al have demonstrated a relation of SF leptin concentrations with the radiographic 
severity of OA in OA patients, suggesting a role of leptin as an effective marker for 
quantitative detection of OA (Ku et al., 2009).  
All these data have focused on the pro-inflammatory effect of leptin in vitro that seems to 
have an adverse effect on cartilage homeostasis. Very recently, Griffin et al, showed that the 
incidence of OA was not higher in ob/ob and db/db female obese mice than in control 
background strain (C57BL/6J). Nevertheless, in this study, no standard was set for the 
incidence of OA in obese control mice without leptin mutation (Griffin et al., 2009). 
This recent result suggested that obesity alone is insufficient to induce systemic 
inflammation and knee OA and that leptin has a necessary role in the pathophysiology of 
OA associated with obesity. 
It is also found a relationship between leptin and lupus disease related factors. In fact, 
patients with SLE have increased concentrations of leptin and these concentrations are 
associated with insulin resistance, BMI (Body Mass Index) and CRP (C-reactive protein) in 
these patients (Chung et al., 2009). Figure 1. 
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Fig. 1. Schematic representation of the effects of leptin in the brain, immune system, and 
articular cartilage. 
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3. Adiponectin 
Adiponectin, also known as GBP28, apM1, Acrp30 or AdipoQ, is a 244-residue protein that 
is produced mainly by WAT. Adiponectin has structural homology with collagens VIII and 
X and complement factor C1q, and it circulates in the blood in relatively large amounts in 
different molecular forms (trimers, hexamers and also 12-18-mer forms) (Kadowaki & 
Yamauchi, 2005; Oh et al., 2007). It increases fatty acid oxidation and reduces the synthesis 
of glucose in the liver. Ablation of the adiponectin gene has no dramatic effect on-knock-out 
mice on a normal diet, but when placed on a high fat/sucrose diet they develop severe 
insulin resistance and exhibit lipid accumulation in muscles (Whitehead et al., 2006). 
Circulating adiponectin levels tend to be low in morbidly obese patients and increase with 
weight loss and with the use of thiazolidinediones which enhance sensitivity to insulin 
(Kadowaki & Yamauchi, 2005; Maeda et al., 2001). 
Adiponectin acts via two receptors, one (AdipoR1) found predominantly in skeletal muscle 
and the other (AdipoR2) in liver. Transduction of the adiponectin signal by AdipoR1 and 
AdipoR2 involves the activation of AMPK, PPAR-ǂ, PPAR-Ǆ and other signalling molecules 
(Kadowaki & Yamauchi, 2005). To note, targeted disruption of AdipoR1 and AdipoR2 
causes abrogation of adiponectin binding and all its metabolic actions (Yamauchi et al., 
2007). 
There is evidence that adiponectin has a wide range of effects in pathologies with 
inflammatory component, such as cardiovascular disease, endothelial dysfunction, type 2 
diabetes, metabolic syndrome, OA and RA (Matsuzawa, 2006). Adiponectin acts as a potent 
modulator of both B and T cells; moreover, it modulates the activity of immune innate 
response by inducing relevant anti-inflammatory factors such as IL 1 receptor antagonist 
and IL-10 (Kadowaki & Yamauchi, 2005).  
In contrast to its previously described protective role in vascular diseases, there is evidence 
that adiponectin might act as a pro-inflammatory factor in joints and it could be involved in 
matrix degradation. Of note, these discrepancies in the functions of adiponectin are linked to 
the level of oligomerization of the protein and opposite actions have been described for both 
low molecular weight and high molecular isoforms (Neumeier et al., 2006). 
Adiponectin levels in RA patients are higher than in healthy subjects (Otero M et al., 2006) 
and multiple studies correlated these adiponectin elevated levels with severity of RA (Ebina 
et al., 2009). Giles and collaborators identified a cross sectional association between serum 
adiponectin levels and radiographic damage in RA patients (Giles et al., 2009), suggesting 
that this adipokine may be a mediator of the paradoxical relationship between increasing 
adiposity and protection from radiographic damage in RA, due to adiponectin circulating 
levels decreasing as adiposity increases. Therefore, considering that adiponectin may have 
negative effects on the joint, this adipokine could be a relevant mediator to the inverse 
relationship between increasing adiposity and radiographic damage observed in RA studies.  
In human synovial fibroblasts adiponectin induces IL-6, one of the main mediators of RA, 
via AMPK, p38, IKKǂ-ǃ and NF-κB, (Tang et al., 2007). Similarly, IL-8 is induced by 
adiponectin through an intracellular pathway involving NF-κB (Katano et al., 2009). A 
recent publication confirms the role of adiponectin in pathogenesis of RA. The authors 
showed that adiponectin is able to induce the expression of vascular endothelial growth 
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factor, MMP-1 and MMP-13, in synovial cells, at the same levels as IL-1ǃ (Choi et al., 2009). 
In line with this, it has been reported that adiponectin, in RA synovial fibroblasts (RASFs), 
increases cyclooxygenase 2 (COX-2), membrane-associated PGE synthase 1 (mPGES-1) and 
prostaglandin E2 (PGE2) mRNA and protein expression in a dose-dependent manner 
(Kusunoki et al., 2010). This increase was inhibited by siRNA against adiponectin receptors 
(AdipoR1 and AdipoR2) or using inhibitors of specific proteins involved in adiponectin 
signal transduction (Kusunoki et al., 2010). 
Adiponectin is also implicated in OA pathogenesis. In chondrocytes this hormone is able 
to induce several pro-inflammatory mediators such as nitric oxide, IL-6, MCP-1, MMP-3 
and MMP-9 as well as IL-8 (Gomez et al., 2011; Lago R et al., 2008), generating a pro-
inflammatory environment at joint level. However, the implication of adiponectin in OA 
development is also supported by clinical observations. Laurberg TB et al have reported 
that plasma adiponectin levels were significantly higher in OA patients than in healthy 
subjects (Laurberg et al., 2009). Moreover, elevated plasma adiponectin levels were 
observed in female patients with erosive compared with non-erosive hand OA (Filkova et 
al., 2009). In addition, adiponectin levels in synovial fluid correlating with osteoarthritis 
severity (Honsawek & Chayanupatkul, 2010) and aggrecan degradation (Hao et al., 2010). 
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Fig. 2. Schematic representation of the interaction of adiponectin with immune cells, 
chondrocytes, and synovial fibroblasts. 
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4. Resistin 
Resistin, known as adipocyte-secreted factor (ADSF) or found in inflammatory zone 3 
(FIZZ3), was discovered in 2001 and was proposed as potential link between obesity and 
diabetes (Steppan et al., 2001). It was secreted by adipose tissue, but has been found also in 
macrophages, neutrophils and other cell types. Serum resistin levels increases with obesity 
in mice, rats and humans (Degawa-Yamauchi et al., 2003; McTernan et al., 2002). Increasing 
evidence indicates its important regulatory roles in various biological processes, including 
several inflammatory diseases.  
There are demonstrations that resistin may be involved in the pathogenesis of RA. It has 
previously been observed increased levels of this adipokine in synovial fluid from patients 
of rheumatoid arthritis (RA) compared to patients with non-inflammatory rheumatic 
disorders (Schaffler et al., 2003). Resistin may be a significant mediator in the inflammatory 
process of RA, in fact the serum resistin levels are associated with disease activity and acute 
phase reactants, including C-reactive protein and IL-1Ra antagonizing IL-1ǃ (Forsblad 
d´Elia et al., 2008; Senolt et al., 2007).  
Resistin has been found in the plasma and synovial fluid of RA patients, and injection of 
resistin into joints of mice induces an arthritis-like condition, with leukocyte infiltration of 
synovial tissues, hypertrophy of the synovial layer, and pannus formation (Bokarewa et al., 
2005; Senolt et al., 2007). Bokarewa et al have showed that resistin induces and is induced by 
several pro-inflammatory cytokines, such as TNF-ǂ or IL-6, in peripheral blood 
mononuclear cells, via NF-kB pathway, indicating that resistin can increase its own activity 
by a positive feedback mechanism (Bokarewa et al., 2005). 
The pro-inflammatory profile of resistin, together with its association with obesity, suggests 
that this adipokine might be another potential mediator that links OA with inflammation 
and obesity. It was demonstrated that this adipokine is elevated in both serum and SF after 
traumatic joint injuries. Recombinant resistin stimulated proteoglycan degradation in mouse 
femoral head cultures and the induction of inflammatory cytokines and PGE2 production. 
Moreover, it inhibited proteoglycan synthesis in human cartilage explants (Lee et al., 2009). 
However, Berry et al have not identified any association between baseline serum levels of 
resistin and cartilage volume loss (Berry et al., 2011). 
In addition, resistin has a role as a marker of inflammation in other rheumatic diseases, such 
as systemic lupus erythematous (SLE). In fact, Almehed et al have demonstrated a positive 
correlation between serum resistin levels, inflammation, bone mineral density and renal 
functions in patients with SLE (Almehed et al., 2008). Figure 3. 
5. Visfatin 
Visfatin, also named pre-B-cell colony-enhancing factor (PBEF) and nicotinamide 
phosphoribosyltransferase (Nampt), was originally discovered in liver, skeletal muscle and 
bone marrow as a growth factor for B-lymphocyte precursors, however it is also secreted by 
visceral fat (Fukuhara et al.,2005; Samal et al., 1994). It is supposed that visfatin had insulin 
mimetic properties, but the role of this adipokine in the modulation of glucose metabolism, 
as well as its binding to insulin receptors is still debate (Fukurara et al., 2005, 2007). 
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Fig. 3. Schematic representation of resistin interaccion among adipocytes, immune cells and 
bone and cartilage cells. 
It has been reported that visfatin is increased in obesity. Moreover, leucocytes from obese 
patients produce higher amounts of visfatin compared with lean subjects, and specifically, 
granulocytes and monocytes are the major visfatin producing cells (Catalan et al., 2011; 
Friebe et al., 2011). However, leucocytes are not the only non-fat cell-type that synthesizes 
visfatin. Macrophages have also been described as a source for visfatin production (Curat et 
al., 2006) and interestingly, this adipokine promoted macrophage survival by reducing 
apoptosis (Li et al., 2008). 
Our group demonstrated that visfatin was increased in RA patients (Otero M et al., 2006), 
these data were also further confirmed by other authors (Rho et al., 2009). To note, enhanced 
visfatin levels are associated with augmented joint damage (Rho et al., 2009). Brentano and 
colleagues reported that visfatin was localized in the site of invasion of synovial tissue in 
joints of RA patients. Moreover it is able to induce IL-6, MMP-1 and MMP-3 in RA synovial 
fibroblasts, as well as IL-6 and TNF-ǂ in monocytes (Brentano et al., 2007), concluding that 
visfatin has relevant pro-inflammatory and catabolic roles in RA pathogenesis and it could 
be considered a potential therapeutic target. 
A recently published study by Busso et al. shows that visfatin is a key mediator in 
inflammatory arthritis. The administration of a visfatin inhibitor to mice with collagen-
induced arthritis reduced arthritis severity with similar effect to that produced by TNF-ǂ 
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inhibitor (Busso et al., 2008). Moreover, pharmacological inhibition of visfatin led to low 
levels of intracellular NAD in inflammatory cells and decreased the production of TNF-ǂ 
and IL-6 in affected joints (Busso et al., 2008). However, the mechanism by which visfatin 
exerts its catabolic effect in arthritic joints is incompletely understood. 
At cartilage level, OA chondrocytes are able to produce visfatin and its expression is 
increased after IL-1ǃ treatment (Gosset et al., 2008). Visfatin administration, like IL-1ǃ, 
enhances PGE2 release. In line with this, visfatin also increases MMP-3 and MMP-13 
synthesis and release, and ADAMTS-4 and ADAMTS-5 expression in mouse articular 
chondrocytes (Gosset et al., 2008). Visfatin decreases aggrecan expression, probably due to 
this increase in the expression of matrix degradative enzymes (Gosset et al., 2008). Taken 
together, these data suggest that visfatin has a catabolic function in cartilage. Table 1. 
6. Chemerin  
Chemerin, also known as tazarotene-induced gene 2 and retinoic acid receptor responder 2 
(RARRES2), is a novel identified chemoattractant adipokine (Wittamer et al., 2003). It is 
secreted as an 18 kDa inactive proprotein and activated by post-translational C-terminal 
cleavage (Zabel et al., 2005). Chemerin acts via the G-coupled receptor chemokine-like 
receptor 1 (CMKLR1 or ChemR23) (Wittamer et al., 2003). Chemerin and its receptor are 
mainly expressed, but not exclusively, in adipose tissue (Bozaoglu et al., 2007), for instance, 
dendritic cells and macrophages express chemerin receptor (Luangsay et al., 2009). 
Endothelial cells also express ChemR23 and it is up regulated by pro-inflammatory 
cytokines such as TNF-ǂ, IL-1ǃ and IL-6 (Kaur et al., 2010). Moreover, chemerin exogenous 
challenge promotes in vitro angiogenesis by inducing cell proliferation, endothelial 
migration and capillary tube formation, critical steps in the development of angiogenesis 
(Kaur et al., 2010). 
Interestingly, chondrocytes express chemerin and its receptor (Berg et al., 2010; Conde et al., 
2011) and IL-1ǃ is able to increase chemerin expression (Conde et al., 2011). In the same way, 
Berg et al. have demonstrated that recombinant chemerin enhances the production of 
several pro-inflammatory cytokines (TNF-ǂ, IL-1ǃ, IL-6 and IL-8), as well as different MMPs 
(MMP-1, MMP-2, MMP-3, MMP 8 and MMP-13) in human articular chondrocytes (Berg et 
al., 2010). These factors play a role in the degradation of the extracellular matrix, by causing 
a breakdown of the collagen and aggrecan framework, which results in the irreversible 
destruction of the cartilage in OA and RA. Moreover, these authors reported that the 
intracellular signalling after ChemR23 activation occurs through p42/44 MAPK and Akt 
phosphorylation. 
Chemerin and ChemR23 expression was found in SLE skin biopsies (Vermi et al., 2005). In 
vitro experiments showed that chemerin acts as a chemotactic factor for plasmacytoid DCs. 
The tissue distribution of this adipokine, located at the luminal side of inflamed blood 
vessels suggest that chemerin is involved in the migration of plasmacytoid DCs and the 
accumulation of this cells in inflamed tissues in SLE patients (Vermi et al., 2005). Moreover, 
De Palma et al. found chemerin expression in renal tubular epithelial cells from SLE patients 
with nephritis (De Palma et al., 2011). These authors, using a transendothelial chemotaxis 
assay, demonstrated that the recruitment of plasmacytoid DCs by TNF-ǂ was mediated by 
chemerin/ChemR23 interaction, may be due to the induction of the cleavage of pro-
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chemerin by TNF-ǂ through the local production of serine proteases in proximal tubular 
epithelial cells (De Palma et al., 2011; Kanalas & Hopfer, 1997; Zabel et al., 2005). Table 1. 
7. Lipocalin 2 
Lipocalin 2 (LCN2), also termed siderocalin, 24p3, uterocalin and neutrophil gelatinase-
associated lipocalin, is a 25 kDa glycoprotein isolated from neutrophil granules, although 
white adipose tissue (WAT) is thought to be the main source (Triebel et al., 1992). The LCN2 
protein has been isolated as a 25 kDa monomer, as a 46 kDa homodimer and in a covalent 
complex with MMP-9, and its cellular receptor, megalin (GP330), was recently described 
(Devireddy et al., 2001). LCN2 is involved in apoptosis of haematopoietic cells (Devireddy 
et al., 2001), transport of fatty acids and iron (Chu et al.,1998), modulation of inflammation 
(Cowland & Borregaard, 1997) among other processes.  
LCN2 has recently been identified in chondrocytes (Owen et al., 2008). In these cells IL-1ǃ, 
leptin, adiponectin, LPS and dexamethasone act as potent modulators of LCN2 expression 
(Conde et al., 2011). Lipocalin 2 is likely to be involved in matrix degradation since it forms 
molecular complexes with MMP-9 (Gupta et al., 2007). 
Recently, Katano and colleagues confirmed that the level of NGAL in SF was significantly 
higher in patients with RA than in those with osteoarthritis. Through proteome analysis 
Katano et al have showed that GM-CSF may contribute to the pathogenesis of RA by the 
upregulation of LCN2 in neutrophils, followed by induction of Catepsin D, transitional 
endoplasmic reticulum ATPase (TERA) and transglutaminase 2 (tg2) in synoviocytes 
(Katano et al., 2009). These enzymes may contribute to the proliferation of synovial cells and 
infiltration of inflammatory cells inside the synovia (Katano et al., 2009). 
Finally, LCN2 is also a candidate biomarker for the early detection of LN (lupus nephritis) 
that is an inflammation of the kidney caused by systemic lupus erythematosus (SLE), which 
is very common in childhood-onset SLE (cSLE). Hinze et al. have demonstrated that urinary 
and plasma NGAL (U-NGAL and P-NGAL) is an excellent candidate as predictive 
biomarker for worsening of cSLE renal and global disease activity. (Hinze et al., 2009).  
Table 1. 
 
Table 1. Visfatin, LCN2 and Chemerin: effects relevant to rheumatic diseases. 
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8. Conclusions 
It is now clear that adipokines have multiple relevant roles in the body, and many research 
efforts are driven to elucidate the intricate network among, metabolic disorders, 
inflammatory diseases and immune system. Although many aspects are still unclear, this 
chapter summarizes the present knowledge on the role of adipokines in certain rheumatic 
diseases. 
Several adipokines have catabolic effects in articular cartilage, however some of them 
showed contradictory results and their involvement in the degeneration of the joint is not 
well understood. 
The data presented here suggest that adipokines could be considered a link between 
metabolism and rheumatic diseases and their signalling pathways may represent innovative 
therapeutic strategies for autoimmune and rheumatic disorders. 
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